BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody

Reuters2025-12-23

** Shares of drugmaker Invivyd IVVD.O rise 1.4% to $2.92 premarket

** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease

** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co

** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection

** Top-line results expected by mid-2026 - IVVD

** Up to last close, stock up ~133% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593497365?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593497365","market":"fut","top_or_hot":-1,"title":"BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody</title></head><body><p>** Shares of drugmaker Invivyd <span>IVVD.O</span>  rise 1.4% to $2.92 premarket</p><p>** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease</p><p>** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co</p><p>** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection</p><p>** Top-line results expected by mid-2026 - IVVD</p><p>** Up to last close, stock up ~133% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody</title></head><body><p>** Shares of drugmaker Invivyd <span>IVVD.O</span>  rise 1.4% to $2.92 premarket</p><p>** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease</p><p>** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co</p><p>** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection</p><p>** Top-line results expected by mid-2026 - IVVD</p><p>** Up to last close, stock up ~133% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVVD","symbol_name":"Invivyd, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4N3XT0M7:1","article_id":"2593497365","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593497365","pubTimestamp":1766491962,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody** Shares of drugmaker Invivyd IVVD.O  rise 1.4% to $2.92 premarket** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection** Top-line results expected by mid-2026 - IVVD** Up to last close, stock up ~133% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVVD":"Invivyd, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"随着制药商开始新冠病毒预防抗体的后期试验，BUZZ-Invivyd上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":0.9},"content_text":"BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody** Shares of drugmaker Invivyd IVVD.O  rise 1.4% to $2.92 premarket** Co says it has started late-stage clinical trial to test its experimental COVID-19 antibody, VYD2311, as a preventive treatment for the disease** Study will enroll 1,770 adults and teens; compare single vs monthly shots to placebo, says co** IVVD says the goal is to offer vaccine alternative for high-risk people seeking protection** Top-line results expected by mid-2026 - IVVD** Up to last close, stock up ~133% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593497365","isCrawlerRequest":true}